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To determine whether failure of procainamide to prevent 
initiation of ventricular tachyarrhythmias during elec-
trophysiologic testing predicted failure of other antiar-
rhythmic regimens, 81 consecutive patients with coro-
nary artery disease whose ventricular tachyarrhythmias 
remained inducible during procainamide administration 
were studied. Overall, 26 (12 %) of 216 subsequent drug 
studies were successful and at least one effective drug 
regimen was identified in 22 (27%) of the 81 patients. 
Drug success was significantly related to the arrhythmia 
induced at baseline study; 7% of drug studies were suc-
cessful in patients with sustained ventricular tachycar-
dia, 24% in patients with ventricular fibrillation, and 
29% in patients with nonsustained ventricular tachy-
cardia. An effective drug regimen was found in 11 (19%) 
of 59 patients with sustained ventricular tachycardia, 4 
(50%) of 8 patients with ventricular fibrillation and 7 
Programmed ventricular stimulation has been employed to 
identify effective antiarrhythmic drug regimens for the treat-
ment of ventricular tachyarrhythmias (1-8). Initial studies 
(1,3) suggested that a completely effective regimen could 
be identified in approximately 70% of patients. However, 
the incidence of short-term drug efficacy has decreased con-
siderably, at least in part because the introduction of more 
aggressive stimulation protocols (9,10) has resulted in ex-
posure of patients to multiple drug studies. Repeated eIec-
trophysiologic testing is costly (11) and demanding (or both 
patient and physician (12) and carries a small but definite 
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(50%) of 14 patients with nonsustained ventricular 
tachycardia. In patients with sustained ventricular 
tachycardia, failure of procainamide to suppress the ar-
rhythmia correlated with failure of other agents used 
singly but not in combination. 
This study supports the view that when procainamide 
fails to prevent initiation of the arrhythmia in patients 
with inducible sustained ventricular tachycardia it is un-
likely that other individual standard agents will be ef-
fective. However, combination regimens may suppress 
the arrhythmia and should be evaluated. In patients with 
nonsustained ventricular tachycardia, all agents should 
be evaluated because failure to respond to procainamide 
does not predict subsequent responses to other agents 
either alone or in combination. 
(J Am Coli CardioI1985;6:410-6) 
risk of complication (13). Therefore, attempts have been 
made to identify those patients who are least likely to re-
spond to medical therapy and/or whom an alternative treat-
ment strategy would be more appropriate (14-16). Waxman 
et al. (14) demonstrated that in patients whose sustained 
ventricular tachyarrhythmias remained inducible during studies 
with procainamide, only 7% of additional drug trials with 
conventional agents were effective. The aim of this study 
was to determine I) whether this relation was dependent on 
the type of inducible ventricular tachyarrhythmia, and 2) 
whether it still pertains in light of the introduction of newer 
investigational agents. 
Methods 
Study patients. The study group consisted of 81 con-
secutive patients with a ventricular tachyarrhythmia induced 
during baseline electrophysiologic study that remained in-
ducible on a maximally tolerated dose of procainamide. In 
no case was the induction of arrhythmia related to acute 
myocardial ischemia or metabolic or electrolyte imbalances. 
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Table I. Demographic Characteristics of 81 Patients With Coronary Artery Disease 
Sustained YT YFib Nonsustained YT 
Patients (no.) 59 8 14 
Age (yr) 61 ± 10 65 ± 7 63 ± 8 
Sex (M/F) 55/4 810 10/4 
Previous MI 57 7 II 
Ejection fraction (%) 28 ± 16 38 ± 16 31 ± 14 
Previous drug trials 1.9 ± 1.5 1.6 ± 1.2 1.2 ± 1.4 
F = female; M = male; MI = myocardial infarction; YFib = ventricular fibrillation; YT = ventricular 
tachycardia. 
Indications for electrophysiologic study included sus-
tained ventricular tachycardia in 33 patients, syncope in 21, 
cardiac arrest in 20 and symptomatic non sustained ventric-
ular tachycardia in 7, There were 73 men and 8 women 
ranging in age from 42 to 84 years (Table I). All patients 
had coronary artery disease and 75 had had a previous myo-
cardial infarction. Ejection fraction, obtained from either 
radionuclide angiography or contrast left ventriculography, 
ranged from 9 to 72% (mean ± SO 33 ± 17 %). 
Before study, the patients had undergone 0 to 6 (mean 
1.8) empiric trials of drug therapy. The ventricular tachy-
arrhythmias induced in the baseline state were sustained 
monomorphic ventricular tachycardia in 59 patients, ven-
tricular fibrillation in 8 and nonsustained ventricular tachy-
cardia in 14. 
EI~ctrophysioIogic study. After written informed con-
sent was obtained (protocol approved by the Hahnemann 
Institutional Review Board on August 2, 1982), patients 
underwent baseline study in the postabsorptive state after 
all antiarrhythmic drugs were discontinued for at least 5 
half-lives. Multiple electrode catheters were inserted under 
local anesthesia and positioned with fluoroscopic guidance 
at the high right atrium, atrioventricular (A V) junction and 
in the right ventricle at the apex or outflow tract, or both. 
In this study left ventricular stimulation was not required 
for initiation of tachycardia. Three surface electrocardio-
graphic leads (I, aVF and V d and intracardiac electrograms 
were simultaneously displayed on a multichannel oscillo-
scope (Electronics for Medicine, VRI6) and recorded on 
magnetic analog tape. Hard copy tracings were obtained 
using an ink-jet recorder (Siemens-Elema Mingograph) at 
paper speeds of 100 to 250 mmls. Programmed electrical 
stimulation was performed with an optically isolated digital 
stimulator (Blood Associates, Ltd.) with rectangular pulses 
of 1 ms duration at twice late diastolic threshold. 
The stimulation protocol included the introduction of sin-
gle, double and triple ventricular extrastimuli during sinus 
rhythm and ventricular pacing at cycle lengths of 600 and 
450 ms at both the right ventricular apex and right ventric-
ular outflow tract. If nonsustained ventricular tachycardia 
Was initiated, the study protocol was continued until either 
sustained ventricular arrhythmia was initiated or the protocol 
was completed. All initiations of arrhythmia were repeated 
at least once; however, in patients with nonsustained ven-
tricular tachycardia, reproducibility was carefully moni-
tored. More than 10 episodes on two separate studies were 
required before the patient was included in the study. 
In subsequent drug follow-up studies, the same ventric-
ular stimulation protocol was completed irrespective of the 
stimulation mode that initiated the arrhythmia in the baseline 
study. 
Definition of terms. Sustained ventricular tachycardia 
was defined as ventricular tachycardia lasting more than 30 
seconds or requiring termination before 30 seconds because 
of hemodynamic compromise or intolerable symptoms 
Nonsustained ventricular tachycardia was defined as an 
episode of ventricular tachycardia that lasted for six or more 
complexes and terminated spontaneously in 30 seconds or 
less. 
Ventricular fibrillation was defined as the initiated rhythm 
if chaotic ventricular activity typical of ventricular fibril-
lation was observed in any surface electrocardiographic lead 
within 3 seconds after the initiation of a sustained arrhythmia. 
Noninducibility was defined as the induction of fewer 
than six repetitive ventricular responses during completion 
of the stimulation protocol. 
Antiarrhythmic drug administration. By study de-
sign, only patients in whom a ventricular tachyarrhythmia 
remained inducible after procainamide administration were 
included. Procainamide was administered intravenously or 
orally, or both, to the maximally tolerated dose, defined as 
development of symptoms of toxicity, an increase of more 
than 25% in QRS duration, lengthening of the QT interval 
to greater than 500 ms on the surface electrocardiogram, or 
hypotension that could not be supported by saline infusion. 
Intravenous procainamide dosage was 1,000 to 2,000 mg 
infused at a rate of 50 mg/min followed by a maintenance 
infusion of 4 to 8 mg/min. Oral procainamide in a sustained 
release preparation was administered in doses of 750 to 
2,000 mg every 6 hours. 
The dosage of the drugs administered in the additional 
follow-up studies was also adjusted to the maximally tol-
erated level in each individual patient or to the maximal 
dose of a study protocol as follows: quinidine gluconate, 
330 to 660 mg every 8 hours orally; mexiletine either in-
travenously, 5 mg/kg at an infusion rate of 10 mg/min fol-
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Table 2. Induced Ventricular Tachyarrhythmia in Relation to Indication for Study 























Abbreviations as in Table I. 
lowed by a maintenance infusion of 4 mg/min, or orally, 
150 to 300 mg every 8 hours; amiodarone, 1,000 mg/day 
for 7 days followed by 800 mg/day, follow-up study being 
undertaken 10 to 14 days after initiation of therapy; lido-
caine, 5 mg/kg intravenously for 15 minutes followed by a 
maintenance infusion of 4 mg/min; disopyramide, 100 to 
300 mg every 6 to 8 hours orally; bethanidine, 1,500 mg/day 
orally; phenytoin, 300 mg/day after a loading dose of 1,000 
mg/day for 2 days; f1ecainide, 100 to 200 mg every 12 hours 
orally; and indecainide, 60 to 100 mg intravenously at an 
infusion rate of 15 J-tg/kg per min, or orally, 50 to 100 mg 
every 8 hours. If the drugs were used in combination, the 
same doses were used except that when procainamide was 
added intravenously to amiodarone, the dose of procain-
amide was limited to 1,000 mg. 
Statistical analysis. Statistical analysis was performed 
using the unpaired t test and analysis of variance for con-
tinuous variables and R x C contingency tables for discrete 
variables. A value of p < 0.05 was considered significant. 
Values are expressed as mean values ± 1 standard deviation. 
Results 
Clinical characteristics. The patients were grouped for 
analysis on the basis of the type of ventricular arrhythmia 
5 of 33 (15%) 
9 of 20 (45%) 
6 of 21 (29%) 
2 of 7 (29%) 
initiated at the baseline study (Table 1). There was no sta-
tistical difference in age or global cardiac function as as-
sessed by ejection fraction among the three groups. The 
induced arrhythmias are listed in Table 2 in relation to the 
indications for study. 
In patients with nonsustained ventricular tachycardia, the 
duration of the longest episode of induced ventricular tachy-
cardia ranged from 14 to 161 complexes (4 to 29 seconds). 
The mean duration of the longest episode was 46 complexes. 
In 3 of the 14 patients, the duration of the longest episode 
was less than 20 complexes. The cycle length of the longest 
episode ranged from 160 to 250 ms (mean = 196). 
The mean serum procainamide concentration at the time 
of electrophysiologic study was 12.1 ± 4.4 J-tg/ml for the 
total group and was not statistically different in each subgroup: 
12.1 ± 4.1 J-tg/ml for patients with sustained ventricular 
tachycardia, 12.0 ± 6.2 J-tg/ml for patients with ventricular 
fibrillation and 12.2 ± 5.9 J-tg/ml for patients with non-
sustained ventricular tachycardia. 
Overall results of drug therapy (Tables 2 and 3). The 
total group of 81 patients underwent 216 additional drug 
studies (range 1 to 5 studies per patient; mean 2.6 ± 1.2). 
Twenty-six (12%) of these studies were successful. This 
represents the identification of at least one effective (lrug 
regimen in 22 (27%) of 81 patients. 
Table 3. Relation of Induced Ventricular Tachyarrhythmia to Subsequent Drug Response 
Patients (no.) 
Studies (no.) 
Studies per patient (mean) 
Drug successes (no.) 
Patients with at least one 
drug success (no.) 
Drug Success 




2.8 ± 1.3 
12 (7%) 
II (19%) 
Nonsustained VT vs sustained VT = P < 0.005 
Sustained VT vs VFib = P < 0.01 
Abbreviations as in Table I. 
VFib Nonsustained VT 
8 14 
25 28 
3.1 ± 1.2 2.0 ± 1.1 
6 (24%) 8 (29%) 
4 (50%) 7 (50%) 
Patient Success 
Nonsustained VFib vs nonsustained VT = NS 
Nonsustained VT vs sustained VT = P < 0.025 
Sustained VT vs VFib = P < 0.05 
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Subsequent drug success was significantly related to the 
arrhythmia induced at baseline study. Twelve (7%) of 163 
drug studies were successful in patients with sustained ven-
tricular tachycardia, 6 (24%) of 25 studies in patients with 
ventricular fibrillation and 8 (29%) of 28 studies in patients 
with nonsustained ventricular tachycardia. The number of 
drug trials required to suppress sustained ventricular tachy-
cardia was significantly less than that needed to suppress 
ventricular fibrillation or nonsustained ventricular tachy-
cardia (p < 0.01 and < 0.005, respectively). There was no 
statistical difference between the number of drug trials re-
quired to suppress ventricular fibrillation and nonsustained 
ventricular tachycardia. 
Study results for individual patients showed that an ef-
fective drug regimen was found in II (19%) of 59 patients 
with sustained ventricular tachycardia, 4 (50%) of 8 patients 
with ventricular fibrillation and 7 (50%) of 14 patients with 
nonsustained ventricular tachycardia. A similar statistical 
difference was apparent in the identification of at least one 
effective drug regimen between patients with either ven-
tricular fibrillation or nonsustained ventricular tachycardia 
and patients with sustained ventricular tachycardia (p < 0.05 
and < 0.025, respectively). 
There was no significant difference between the mean 
serum procainamide concentration in patients responding to 
another drug regimen compared with those who responded 
to no other regimen (11.9 ± 4.0 versus 12.0 ± 4.9 JLg/ml). 
Individual drug regimen efficacy (Table 4). In the total 
study group, drug success was obtained using quinidine, 
mexiletine and amiodarone, both individually and in com-
bination. In addition, flecainide was effective in one patient 
with sustained ventricular tachycardia. Because of the small 
number of trials involving certain drugs, only regimens used 
in 15 or more studies were analyzed separately. 
Quinidine was successful in a total of 4 (9%) of 47 
studies, mexiletine in 2 (6%) of 33 studies, amiodarone in 
9 (17%) of 54 studies, quinidine and mexiletine in com-
bination in 6 (19%) of 32 studies, procainamide and mex-
iletine in combination in 3 (20%) of 15 studies and amio-
darone and procainamide in combination in I (6%) of 17 
studies. 
Individual drllg efficacy and arrhythmia type. Certain 
trends were apparent in relation to the effectiveness of a 
particular drug regimen and the type of induced arrhythmia. 
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Quinidine was successful in suppressing ventricular fibril-
lation in only I of 7 trials and was ineffective in suppressing 
sustained ventricular tachycardia in all 34 trials. In contrast, 
quinidine successfully suppressed non sustained ventricular 
tachycardia in three (50%) of six trials (p < 0.025). A 
similar differential pattern was observed with mexiletine. 
This agent was ineffective in suppressing sustained ven-
tricular tachycardia in all 19 trials and in suppressing ven-
tricular fibrillation in all 4 trials but successfully suppressed 
nonsustained ventricular tachycardia in 2 (20%) of 10 studies 
(p < 0.005). 
Amiodarone was studied in 44 patients with sustained 
ventricular tachycardia, 5 patients with ventricular fibril-
lation and 5 patients with nonsustained ventricular tachy-
cardia; it was effective in 7 (16%), 0 and 2 (40%) studies, 
respectively. 
Despite the infrequent success of quinidine and mexi-
letine individually, in suppressing sustained arrhythmias, 
the combination of quinidine and mexiletine was successful 
in 2 (40%) of 5 trials in patients with ventricular fibrillation 
and 4 (17%) of 24 trials in patients with sustained ventricular 
tachycardia. The combination was used in only three studies 
in patients with nonsustained ventricular tachycardia and 
proved unsuccessful in all three. 
The combination of procainamide and mexiletine was 
unsuccessful in the II studies in patients with sustained 
ventricular tachycardia, but was effective in I of 2 studies 
in patients with nonsustained ventricular tachycardia and in 
2 of 2 studies in patients with ventricular fibrillation. 
The combination of amiodarone and procainamide had 
a low success rate in suppressing sustained ventricular tachy-
cardia, being effective in only I (7%) of 14 trials. It was 
also ineffective in two trials in patients with ventricular 
fibrillation and the single trial in a patient with non sustained 
ventricular tachycardia. 
There were no significant differences in the mean serum 
concentrations of quinidine, mexiletine and amiodarone be-
tween patients who did and did not respond to these regi-
mens (Table 5). 
Discussion 
The selection of drug therapy by electrophysiologic test-
ing has been a major advance in the treatment of life-
Table 4. Responses to Subsequent Drug Tests Categorized by Baseline Arrhythmia 
Sustained YT YFib Nonsustained YT 
Quinidine 0(0%) of 34 I (14%) of 7 3 (50%) of 6 
Mexiletine 0(0%) of 19 0(0%) of 4 2 (20%) of 10 
Amiodarone 7 (16%) of 44 0(0%) of 5 2 (40%) of 5 
Quinidine + mexiletine 4 (17%) of 24 2 (40%) of 5 0(0%) of 3 
Procainamide + mexiletine 0(0%) of II 2 (100%) of 2 I (50%) of 2 
Amiodarone + procainamide 1 (7%) of 14 o (0%) of2 0(0%) of 1 
Abbreviations as in Table I. 
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Table 5. Serum Drug Levels (p,g/ml) During Subsequent 
Drug Tests 
Drug Responders Nonresponders 
Quinidine 2.4 ± 0.8 3.1 ± 1.3 (NS) 
Mexiletine 1.6 ± 0.6 1.1 ± 0.6 (NS) 
Amiodarone 1.6 ± 0.6 1.6 ± 0.7 (NS) 
NS = not significantly different compared with responders. 
threatening ventricular tachyarrhythmias (1-8). The initial 
studies in patients with recurrent sustained ventricular tachy-
cardia (1-4) were extended to include patients with out-of-
hospital cardiac arrest (5,7,8). These studies have demon-
strated that non inducibility of a previously inducible base-
line tachyarrhythmia during short-term drug therapy reliably 
predicts the long-term efficacy of that treatment. 
Prospective identification of drug responders. Un-
fortunately, the identification of an effective drug regimen 
may require the patient to undergo repeated studies, incur-
ring the risk of complication inherent in any invasive pro-
cedure (13) and the associated psychological stress, which 
is an important component of overall patient morbidity. To 
reduce the exposure of patients to an empirically selected 
battery of therapies, two approaches have been employed. 
Spielman et al. (15) and Swerdlow et al. (16), using mul-
tivariate analysis, identified several clinical variables that, 
when combined in a discriminant function, define patients 
with low probability for overall drug success. These patients 
can be offered a different therapeutic intervention at an 
earlier stage. An alternative strategy uses the results of 
administration of one drug to predict the efficacy of other 
medications. Swiryn et al. (17) found a concordant response 
to procainamide and quinidine in 83% of patients with ven-
tricular tachycardia (p < 0.025); in contrast; only 71 % re-
sponded to disopyramide, and the correlation between the 
responses to procainamide and disopyramide was not sta-
tistically significant. This result suggested that the class I 
agents procainamide and quinidine had concordant effects 
and the response to one could be used to predict the effect 
of the other. The concordance did not apply to disopyr-
amide, however, which also possesses class I activity. 
The use of procainamide to predict response to other 
drugs was analyzed further by Waxman et al. (\4), whose 
study demonstrated that in patients with sustained ventric-
ular tachyarrhythmias that remained inducible on procain-
amide, only 10 (7%) of 145 additional drug regimens were 
successful. These investigators also stressed, as previously 
documented by Greenspan et al. (18), that high doses of 
procainamide are required before this drug can be assumed 
to have failed. 
Influence of arrhythmia type on drug response. Both 
previous studies employed conventional drugs and did not 
include investigational agents such as amiodarone or mex-
iletine. Neither study addressed the relation between con-
cordance of drug response and arrhythmia type. In the study 
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by Swiryn et al. (17), all patients had inducible sustained 
ventricular tachycardia and in the study by Waxman et al. 
(14), although 10 of the 126 patients had ventricular fibril-
lation, these patients were not analyzed separately. A dif-
ference is response of various types of arrhythmia to drug 
therapy was suggested by Swerdlow (19) and Schoenfeld 
(20) and their associates. In the study by Swerdlow et al. 
(19), induced sustained ventricular tachycardia was more 
easily suppressed by drug therapy than either ventricular 
fibrillation or nonsustained ventricular tachycardia whereas 
Schoenfeld et al. (20) observed that drug suppression was 
less successful for sustained ventricular tachycardia than for 
ventricular fibriIIation or nonsustained ventricular tachy-
cardia. Although comparison of studies is difficult because 
of differences in patient selection, stimulation protocols and 
drug therapy, these results suggest that in studies of con-
cordance of drug response, definition of the arrhythmia type 
may be important. The results of our study are consistent 
with the observations of Schoenfeld et al. (20). 
Despite failure of procainamide therapy, successful ar-
rhythmia suppression was obtained in 29% of drug trials in 
patients with nonsustained ventricular tachycardia and in 
24% of trials in patients with ventricular fibriIlation. Among 
patients with sustained ventricular tachycardia, only 7% of 
subsequent drug studies were effective. This response is 
identical to that reported by Waxman et al. (14) despite the 
use of newer investigational agents in our study. However, 
with respect to patient management, it is more important to 
determine the predictive value for identification of a suc-
cessful drug regimen for each individual patient. In the 
groups nonsustained ventricular tachycardia and ventricular 
fibrillation, an effective therapy was obtained for 50% of 
the patients. Although the drug success rate was low in 
sustained ventricular tachycardia, at least one successful 
regimen was stiII identified in 19% of these patients. Thus, 
even in sustained ventricular tachycardia, failure of pro-
cainamide does not preclude the effectiveness of alternate 
drug therapy in a substantial number of cases. 
Concordance of drug responses. The concordant re-
lation between failure of procainamide and subsequent fail-
ure of quinidine in previous studies of sustained ventricular 
tachyarrhythmias is fully supported by the present study but 
this does not hold true for nonsustained ventricular tachy-
cardia. The same pattern of dependence on arrhythmia type 
was also observed with the investigational agent mexiletine, 
which has a different class I cellular electrophysiologic ac-
tion than quinidine (21). These observations emphasize the 
importance of defining the type of arrhythmia when dis-
cussing predictability of drug response. Whether this vari-
able response is an expression of differing underlying elec-
trophysiologic mechanisms was not specifically addressed 
in our study. Certainly, patients with inducible sustained 
ventricular tachycardia have a greater prevalence of previous 
myocardial infarction and poorer cardiac function than do 
patients with either ventricular fibrillation or nonsustained 
JACC Vol. 6. No.2 
August 1985:410-6 
ventricular tachycardia, factors that have previously been 
shown to be important in predicting success or failure of 
drug therapy (15,16). However, this does not negate the 
implications of the study with respect to drug efficacy. 
Unlike single agents, some drug combinations were suc-
cessful in suppressing sustained arrhythmias in our study. 
Although Ross et al. (22) demonstrated that inefficacy of 
several class I agents individually predicted their inefficacy 
in combination, DiMarco et al. (23) found that the combi-
nation of quinidine and mexiletine was effective in 7 of 35 
patients who did not respond to quinidine alone. Although 
the numbers are small in their study and ours, combination 
regimens are worthy of further study. 
Because concordance of drug response may depend, at 
least in part, on similarities in mechanism of drug action, 
the inability of failure of procainamide to predict failure of 
amiodarone is not surprising. Amiodarone has class III an-
tiarrhythmic activity (24), its main effect being to prolong 
action potential duration. In our study, the success rate of 
amiodarone for complete suppression of induced ventricular 
fibrillation and sustained ventricular tachycardia was 15%, 
which is similar to that of previous studies (24,25). 
Clinical significance of inducible nonsustained ven-
tricular tachycardia. The clinical significance of induced 
nonsustained ventricular tachycardia has been questioned 
(26,27). Although other investigators (5,28) have also used 
nonsustained ventricular tachycardia as an acceptable end 
point during electrophysiologic testing, this issue remains 
controversial. Morady et al. (26), using criteria identical to 
ours, recently identified II patients with induced nonsus-
tained ventricular tachycardia whose follow-up course was 
benign. However, they also identified three other patients 
in whom induced ventricular tachycardia ranged from 17 to 
50 complexes in duration and required treatment. The in-
ducible nonsustained ventricular tachycardia in our study 
differed from that reported by Morady et al. despite the use 
of identical criteria. Whereas the ventricular tachycardia in 
their study had a mean duration of 14 complexes, this was 
the minimal duration in our study. In addition, the duration 
of ventricular tachycardia exceeded 20 complexes in I of 
14 of their patients compared with I I of 14 of our patients. 
Furthermore, all of our patients had symptoms in association 
with their arrhythmia. Similarly, the nonsustained ventric-
ular tachycardia in our group was of greater duration and 
more symptomatic than that reported by others (27). Despite 
these differences among studies, the clinical significance of 
inducible nonsustained ventricular tachycardia remains de-
batable and further study is necessary before consensus can 
be formed. 
Conclusions. Our study supports the view that patients 
with inducible sustained ventricular tachyarrhythmia who 
do not respond to procainamide are unlikely to respond to 
quinidine. Our data also extend this observation to the newer 
investigational agent, mexiletine. It is our current practice, 
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in patients with sustained ventricular tachycardia or fibril-
lation who do not respond to procainamide, to consider use 
of type IA and type IB agents in combination rather than 
individually. However, in patients with nonsustained ven-
tricular tachycardia, all individual agents should be evalu-
ated because of the high likelihood of response. 
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